A Phase 2/3 interventional study of Moxifloxacin and Placebo in Endophthalmitis, sponsored by Jason Ahee, M.D.. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Jason Ahee, M.D. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing moxifloxacin in Endophthalmitis — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Endophthalmitis.
Among the 11 studies testing moxifloxacin in Endophthalmitis, this one has the largest planned enrollment, is the only one that started in 2027, is the only one in phase 2/3, and was the 5th registered.
65 studies on the registry are indexed under Endophthalmitis; 9 are open to participants now.
Browse Endophthalmitis studies →1 of the 11 studies testing moxifloxacin in Endophthalmitis is open now, in 1 country.
By country, each count listing its studies:
Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →
Of the 5 Endophthalmitis studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3 · Phase 4 5
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60,000 is above the median of 111 across 40 interventional studies indexed under Endophthalmitis.
Median enrollment 128 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Jason Ahee, M.D. as lead sponsor.
Jason Ahee, M.D. has 1 study filed under Endophthalmitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing moxifloxacin in Endophthalmitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intracameral injection of moxifloxacin solution after cataract surgery
Drug: Moxifloxacin
Intracameral injection of placebo after cataract surgery
Drug: Placebo
Intracameral injection
Also known as: active
intracameral injection
Also known as: sham
Endophthalmitis after cataract surgery
Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.
Time frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Oct 2030, 40 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin